4.5 Article

Cathepsin L expression is up-regulated by hypoxia in human melanoma cells:: role of its 5′-untranslated region

Journal

BIOCHEMICAL JOURNAL
Volume 413, Issue -, Pages 125-134

Publisher

PORTLAND PRESS LTD
DOI: 10.1042/BJ20071255

Keywords

cathepsin L; hypoxia; internal ribosome entry site (IRES); tumour progression

Ask authors/readers for more resources

Overexpression of cathepsin L, a cysteine protease, and consequently procathepsin L secretion switch the phenotype of human melanoma cells to highly tumorigenic and strongly metastatic. This led us to identify the DNA regulatory sequences involved in the regulation of cathepsin L expression in highly metastatic human melanoma cells. The results of the present study demonstrated the presence of regulatory sequences in the 3' region downstream of the cathepsin L gene and in the 3'- and 5'-flanking regions of GC/CCAAT sites of its promoter. In addition, we established that the 5'-UTR (untranslated region) was the most important region for cathepsin L expression. This 5'-UTR integrated an alternative promoter and sequences involved in post-transcriptional regulation. Transfection experiments of bicistronic reporter vectors and RNAs demonstrated that the cathepsin L 5'-UTR contained a functional IRES (internal ribosome entry site). This complete IRES was present only in one of the three splice variants, which differed in their 5'-UTR. Then, we analysed cathepsin L expression in this human melanoma cell line grown under hypoxia. We demonstrated that under moderate hypoxic conditions (1 % O-2) intracellular expression of cathepsin L was up-regulated. Hypoxia significantly increased only the expression of the transcript which contains the complete IRES, but inhibited promoter activity. These results suggest that the presence of an IRES allowed cathepsin L mRNA translation to be efficient under hypoxic conditions. Altogether, our results indicated that in vivo a tumour hypoxic environment up-regulates cathepsin L expression which promotes tumour progression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus

Tiphaine Delaunay, Carole Achard, Nicolas Boisgerault, Marion Grard, Tacien Petithomme, Camille Chatelain, Soizic Dutoit, Christophe Blanquart, Pierre-Joseph Royer, Stephane Minvielle, Lisa Quetel, Clement Meiller, Didier Jean, Delphine Fradin, Jaafar Bennouna, Antoine Magnan, Laurent Cellerin, Frederic Tangy, Marc Gregoire, Jean-Francois Fonteneau

JOURNAL OF THORACIC ONCOLOGY (2020)

Article Oncology

Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival

Lisa Quetel, Clement Meiller, Jean-Baptiste Assie, Yuna Blum, Sandrine Imbeaud, Francois Montagne, Robin Tranchant, Julien de Wolf, Stefano Caruso, Marie-Christine Copin, Veronique Hofman, Laure Gibault, Cecile Badoual, Ecaterina Pintilie, Paul Hofman, Isabelle Monnet, Arnaud Scherpereel, Francoise Le Pimpec-Barthes, Jessica Zucman-Rossi, Marie-Claude Jaurand, Didier Jean

MOLECULAR ONCOLOGY (2020)

Review Oncology

The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models

Christophe Blanquart, Marie-Claude Jaurand, Didier Jean

FRONTIERS IN ONCOLOGY (2020)

Letter Oncology

Reply to: Oncolytic Viral Therapy for Malignant Pleural Mesothelioma

Didier Jean, Tiphaine Delaunay, Clement Meiller, Nicolas Boisgerault, Marion Grard, Stefano Caruso, Christophe Blanquart, Emanuela Felley-Bosco, Jaafar Bennouna, Frederic Tangy, Marc Gregoire, Jean-Francois Fonteneau

JOURNAL OF THORACIC ONCOLOGY (2020)

Article Oncology

Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma

Thibaut Blondy, Senan Mickael d'Almeida, Tina Briolay, Julie Tabiasco, Clement Meiller, Anne-Laure Chene, Laurent Cellerin, Sophie Deshayes, Yves Delneste, Jean-Francois Fonteneau, Nicolas Boisgerault, Jaafar Bennouna, Marc Gregoire, Didier Jean, Christophe Blanquart

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Article Genetics & Heredity

Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma

Clement Meiller, Francois Montagne, Theo Z. Hirsch, Stefano Caruso, Julien de Wolf, Quentin Bayard, Jean-Baptiste Assie, Lea Meunier, Yuna Blum, Lisa Quetel, Laure Gibault, Ecaterina Pintilie, Cecile Badoual, Sarah Humez, Francoise Galateau-Salle, Marie-Christine Copin, Eric Letouze, Arnaud Scherpereel, Jessica Zucman-Rossi, Francoise Le Pimpec-Barthes, Marie-Claude Jaurand, Didier Jean

Summary: This study investigated intra-tumor heterogeneity in malignant pleural mesothelioma (MPM) using the largest series to date and multi-omics profiling of a substantial series of multi-site tumor samples. The results revealed patient-dependent spatial heterogeneity at genetic, transcriptomic, and epigenetic levels, as well as changes in the immune landscape of the tumor microenvironment, supporting the need for multi-sampling for precision medicine.

GENOME MEDICINE (2021)

Article Medicine, Research & Experimental

KRAS signaling in malignant pleural mesothelioma

Antonia Marazioti, Anthi C. Krontira, Sabine J. Behrend, Georgia A. Giotopoulou, Giannoula Ntaliarda, Christophe Blanquart, Hasan Bayram, Marianthi Iliopoulou, Malamati Vreka, Lilith Trassl, Mario A. A. Pepe, Caroline M. Hackl, Laura Klotz, Stefanie A. Weiss, Ina Koch, Michael Lindner, Rudolph A. Hatz, Juergen Behr, Darcy E. Wagner, Helen Papadaki, Sophia G. Antimisiaris, Didier Jean, Sophie Deshayes, Marc Gregoire, Ozgecan Kayalar, Deniz Mortazavi, Sukru Dilege, Serhan Tanju, Suat Erus, Omer Yavuz, Pinar Bulutay, Pinar Firat, Ioannis Psallidas, Magda Spella, Ioanna Giopanou, Ioannis Lilis, Anne-Sophie Lamort, Georgios T. Stathopoulos

Summary: A portion of human MPM cases have mutations in KRAS, and mouse models suggest that KRAS mutations can lead to MPM, especially when combined with TP53 deletion. These findings indicate that KRAS alterations may play an important and underestimated role in certain MPM patients.

EMBO MOLECULAR MEDICINE (2022)

Article Oncology

A Community-Driven, Openly Accessible Molecular Pathway Integrating Knowledge on Malignant Pleural Mesothelioma

Marvin Martens, Franziska Kreidl, Friederike Ehrhart, Didier Jean, Merlin Mei, Holly M. Mortensen, Alistair Nash, Penny Nymark, Chris T. Evelo, Ferdinando Cerciello

Summary: Malignant pleural mesothelioma (MPM) is a highly aggressive malignancy mainly triggered by exposure to asbestos and characterized by complex biology. The research community has generated a significant body of knowledge over the decades to improve understanding of the disease for prevention, diagnostics, and new treatments. Developing integrated tools for accessing and analyzing data can aid scientists in studying and comprehending MPM more effectively.

FRONTIERS IN ONCOLOGY (2022)

Article Oncology

Heterogeneous RNA editing and influence of ADAR2 on mesothelioma chemoresistance and the tumor microenvironment

Ananya Hariharan, Weihong Qi, Hubert Rehrauer, Licun Wu, Manuel Ronner, Martin Wipplinger, Jelena Kresoja-Rakic, Suna Sun, Lucia Oton-Gonzalez, Marika Sculco, Veronique Serre-Beinier, Clement Meiller, Christophe Blanquart, Jean-Francois Fonteneau, Bart Vrugt, Jan Hendrik Ruschoff, Isabelle Opitz, Didier Jean, Marc de Perrot, Emanuela Felley-Bosco

Summary: This study found increased levels of ADAR-mediated RNA editing in mesothelioma tumors and primary cultures compared to mesothelial cells. Heterogeneity in editing was observed between tumor samples and primary cultures. ADAR2 expression levels were higher in BRCA1-associated protein 1 wild-type tumors and correlated with changes in RNA editing in transcripts and 3'UTR. ADAR2 was found to play a role in cell proliferation, cell cycle, sensitivity to antifolate treatment, and type-1 interferon signaling, leading to changes in the microenvironment in vivo.

MOLECULAR ONCOLOGY (2022)

Article Biochemistry & Molecular Biology

The Pattern of RNA Editing Changes in Pleural Mesothelioma upon Epithelial-Mesenchymal Transition

Emanuela Felley-Bosco, Weihong Qi, Didier Jean, Clement Meiller, Hubert Rehrauer

Summary: This study reveals the association between RNA editing and the epithelial-mesenchymal transition (EMT) phenotype in pleural mesothelioma (PM). Analysis of RNA editing expression changes in PM samples showed increased editing in introns and decreased editing in 3' UTR in samples with EMT phenotype.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Oncology

Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition

Sabine Paternot, Eric Raspe, Clement Meiller, Maxime Tarabichi, Jean-Baptiste Assie, Frederick Libert, Myriam Remmelink, Xavier Bisteau, Patrick Pauwels, Yuna Blum, Nolwenn Le Stang, Severine Tabone-Eglinger, Francoise Galateau-Salle, Christophe Blanquart, Jan P. Van Meerbeeck, Thierry Berghmans, Didier Jean, Pierre P. Roger

Summary: This study evaluated the impact of CDK4/6 inhibition by palbociclib in malignant pleural mesothelioma (MPM) and found that MPM is uniquely sensitive to CDK4/6 inhibitors. Palbociclib can durably inhibit cell proliferation, even after drug washout, and induce a senescence-associated secretory phenotype. The study supports the evaluation of CDK4/6 inhibitors as monotherapy or combination therapy for MPM treatment.

MOLECULAR ONCOLOGY (2022)

Article Immunology

Deep dive into the immune response against murine mesothelioma permits design of novel anti-mesothelioma therapeutics

Esther Stern, Stefano Caruso, Clement Meiller, Inbal Mishalian, Theo Z. Hirsch, Quentin Bayard, Carmit T. Tadmor, Hanna Wald, Didier Jean, Ori Wald

Summary: In this study, the AB12 murine mesothelioma model was thoroughly characterized to improve its accuracy in predicting the response of human malignant pleural mesothelioma (hMPM) to immunotherapy. The study found that different stages of tumors have different responses to immunotherapy, with intermediate tumors showing the best response and advanced tumors showing a weakening response. Additionally, the addition of cisplatin to the standard-of-care immunotherapy improved mice survival and enhanced the anti-tumor response in advanced tumors.

FRONTIERS IN IMMUNOLOGY (2023)

Meeting Abstract Oncology

MESOMICS Project: Using Whole-Genome Sequencing Data to Fill the Gaps in Malignant Pleural Mesothelioma Molecular Studies

L. Mangiante, N. Alcala, A. Di Genova, A. Sexton-Oates, N. Le Stang, S. Boyault, C. Cuenin, F. Damiola, C. Voegele, M. Mesobank, D. Jean, S. Lantuejoul, A. Ghantous, H. Hernandez-Vargas, C. Caux, N. Girard, N. Lopez-Bigas, L. B. Alexandrov, F. Galateau Salle, M. Foll, L. Fernandez-Cuesta

JOURNAL OF THORACIC ONCOLOGY (2022)

Meeting Abstract Oncology

Spatial intra-tumor molecular heterogeneity in malignant pleural mesothelioma.

Clement Meiller, Francois Montagne, Theo Z. Hirsch, Stefano Caruso, Julien de Wolf, Quentin Bayard, Jean-Baptiste Assie, Lea Meunier, Yuna Blum, Lisa Quetel, Laure Gibault, Ecaterina Pintilie, Cecile Badoual, Marie-Christine Copin, Eric Letouze, Arnaud Scherpereel, Jessica Zucman-Rossi, Francoise Le Pimpec-Barthes, Marie-Claude Jaurand, Didier Jean

CANCER RESEARCH (2021)

Meeting Abstract Oncology

Discovery of YAP-TEAD protein-protein interaction inhibitors (PPI) for treating malignant pleural mesothelioma (MPM).

Anne Soude, Martine Barth, Jean-Michel Luccarini, Severine Delaporte, Florence Chirade, Christelle Valaire, Aude Boulay, Genevieve Cheret, Marie Dorchie, Celine Estivalet, Pascale Tuya-Boustugue, Robin Tranchand, Didier Jean, Lisa Quetel, Jean-Baptiste Assie, Irena Konstantinova, Jean-Louis Junien, Pierre Broqua

MOLECULAR CANCER RESEARCH (2020)

No Data Available